IMproving PULmonary hypertension Screening by Echocardiography: IMPULSE

Table 2 Clinical and haemodynamic parameters in those with either low, intermediate or high BSE/ESC TTE PH probability (N = 310)

TTE parameters	Low (N = 78)	Intermediate (N = 68)	High (N = 164)
PAH	4	17	42
LHD	19	14	28
CTEPH	5	11	64
Lung disease		2	6
Multifactorial/unclear		6	18
No PH	50	18	6
Haemodynamic data	(N = 78)	(N = 68)	(N = 164)
mPAP (mmHg)	31.3 ± 6.9	37.4 ± 9.7	46.3 ± 11.2
PVR (mmHg)	3.0 ± 1.6	5.4 ± 3.2	7.7 ± 3.8
PCWP (mmHg)	15.1 ± 4.8	14.1 ± 5.4	16.9 ± 6.1
PA sats (%)	71.6 ± 4.0	66.1 ± 8.2	63.0 ± 8.7
CO (L/min)	5.1 ± 1.4	4.7 ± 1.3	4.3 ± 1.2
CI ((L/min/m²)	2.8 ± 0.7	2.5 ± 0.7	2.4 ± 0.6
NT Pro BNP (ng/L)	321.1 ± 341.6	1039.7 ± 1393.9	2282.5 ± 2995.5
6MWT (m)	318.9 ± 178.7	298.6 ± 164.4	262.7 ± 144.7

PAH pulmonary arterial hypertension, LHD left heart disease, CTEPH chronic thromboembolic pulmonary hypertension, mPAP mean pulmonary artery pressure, PVR pulmonary vascular resistance, PCWP pulmonary capillary wedge pressure, PA sats pulmonary artery saturations, CO cardiac output, CI cardiac index, NT pro BNP N-terminal pro hormone of brain natriuretic peptide, 6MWT six-min walk test

ISSN: 2055-0464